Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Sarah Noonberg, M.D., Ph.D.

May 17, 2023

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Sarah Noonberg, M.D., Ph.D., to its Board of Directors.

“Sarah is an accomplished healthcare executive with extensive global clinical development and corporate strategy experience,” said Scott Braunstein, M.D., Chairman and Chief Executive Officer of Marinus. “With a track record of successfully advancing programs in various therapeutic areas using diverse modalities, a deep understanding of orphan diseases and over a decade of experience as a hospitalist physician, her unique perspective will be invaluable to our strategic decision-making as we shape our organization's future and evaluate opportunities to expand our pipeline into other rare epilepsy disorders.”

Dr. Noonberg is a physician-scientist with a diverse background in translational science, clinical development, medical affairs and corporate governance. She has significant experience designing and leading rare disease programs from discovery to global regulatory approvals and commercialization. Dr. Noonberg currently serves as the Chief Medical Officer of Metagenomi, a privately held genomics company, where she is advancing its gene editing technology platform toward the clinic. She previously served as Chief Medical Officer of Maze Therapeutics, Nohla Therapeutics and Prothena Biosciences and prior to that, held clinical development executive leadership roles at BioMarin and at Medivation. Her industry experience is complemented by more than 10 years of experience treating patients as a hospitalist physician.

“Marinus has emerged as a leader in the development of innovative treatment options for patients with genetic epilepsies and seizure disorders. With a passion for innovation and improving clinical outcomes for patients with rare diseases, I look forward to working with the Marinus team to advance the company’s current and future goals,” said Sarah Noonberg, M.D., Ph.D.

Dr. Noonberg currently serves on the Board of Directors at Protagonist Therapeutics and Neoleukin Therapeutics. She trained in internal medicine at Johns Hopkins Hospital, received an M.D. from the University of California, San Francisco, a Ph.D. in bioengineering from the University of California, Berkeley, and a bachelor’s degree in engineering science from Dartmouth College.

About Marinus Pharmaceuticals

Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company’s commercial product, ZTALMY® (ganaxolone) oral suspension CV, has been approved by the U.S. FDA for the treatment of seizures associated with CDKL5 deficiency disorder in patients two years of age and older. The potential of ganaxolone is also being studied in other rare seizure disorders, including in Phase 3 trials in tuberous sclerosis complex and refractory status epilepticus. Ganaxolone is a neuroactive steroid GABAA receptor modulator that acts on a well-characterized target in the brain known to have anti-seizure effects. It is being developed in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings. For more information visit

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may", "will", "expect", "anticipate", "estimate", "intend", "believe", and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, our commercial and clinical strategy, development plans and timelines, and other future events.

Forward-looking statements in this press release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, unexpected market acceptance, payor coverage or future prescriptions and revenue generated by ZTALMY; unexpected actions by the FDA or other regulatory agencies with respect to our products; competitive conditions and unexpected adverse events or patient outcomes from being treated with ZTALMY, uncertainties and delays relating to the design, enrollment, completion, and results of clinical trials; unanticipated costs and expenses; the company’s cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; our ability to comply with the FDA’s requirement for additional post-marketing studies in the required time frames; the timing of regulatory filings for our other product candidates; clinical trial results may not support regulatory approval or further development in a specified indication or at all; actions or advice of the FDA or EMA may affect the design, initiation, timing, continuation and/or progress of clinical trials or result in the need for additional clinical trials; the size and growth potential of the markets for the company’s product candidates, and the company’s ability to service those markets; the company’s expectations, projections and estimates regarding expenses, future revenue, capital requirements, and the availability of and the need for additional financing; delays, interruptions or failures in the manufacture and supply of our product candidates; the company’s ability to obtain additional funding to support its clinical development and commercial programs; and the effect of the COVID-19 pandemic on our business, the medical community, regulators and the global economy. This list is not exhaustive and these and other risks are described in our periodic reports, including our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Sasha Damouni Ellis
Senior Vice President, Corporate Affairs & Investor Relations
Marinus Pharmaceuticals, Inc.

Source: Marinus Pharmaceuticals